Skip to main content
SpringerLink
Log in

Ruboxistaurin

LY 333531

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Eli Lilly and Company, Alcon Inc. Lilly and Alcon Sign Marketing Collaboration for Potentially the First Oral Medication for Diabetic Retinopathy. Media Release: 21 Jul 2006. Available from URL: http://www.lilly.com

    Google Scholar 

  2. Eli Lilly and Company Japan KK, Takeda. Lilly and Takeda Sign a Joint Development/Co-Marketing Agreement on Ruboxistaurin Mesylate, An Agent for the Treatment of Diabetic Microvascular Complications. Media Release: 18 Dec 2003. Available from URL: http://www.lilly.com

    Google Scholar 

  3. Eli Lilly and Company. Lilly Reports Second-Quarter EPS of $.76. Media Release: 21 Jul 2006. Available from URL: http://www.lilly.com

    Google Scholar 

  4. Eli Lilly and Company. Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study. Media Release: 13 Nov 2006. Available from URL: http://www.lilly.com

    Google Scholar 

  5. Joslin Diabetes Center. Joslin-chaired Study Shows New Compound May Reduce Risk of Vision Loss in Patients With Diabetes. Media Release: 14 Jul 2005. Available from URL: http://www.joslin.org

    Google Scholar 

  6. Eli Lilly and Company. Data Indicate That Lilly’s Ruboxis- taurin May Have A Potentially Beneficial Effect on Diabetes-Induced Eye Disease. Media Release: 26 Oct 2004. Available from URL: http://www.lilly.com

    Google Scholar 

  7. Eli Lilly and Company. Data Presented at International Diabetes Meeting Reveals Lilly’s Ruboxistaurin Mesylate May Delay Progression of Diabetic Macular Edema. Media Release: 25 Aug 2003. Available from URL: http://www.lilly.com

    Google Scholar 

  8. Eli Lilly and Company. Lilly Reports $.68 Earnings Per Share in the First Quarter. Media Release: 18 Apr 2005. Available from URL: http://www.lilly.com

    Google Scholar 

  9. Eli Lilly and Company. Merrill Lynch Pharmaceutical, Biotech nology and Medical Device Conferance. Company Communication: [10 pages], 4 Feb 2004. Available from URL: http://investor.lilly.com

    Google Scholar 

  10. Demolle D, De Suray J-M, Onkelinx C. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC-beta inhibitor. Clinical Pharmacology and Therapeutics 65: 189, Feb 1999

    Google Scholar 

  11. Pereira A, De Suray J-M, Onkelinx C. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC-beta inhibitor in healthy elderly subjects. Diabetes 48 (Suppl. 1): 361, May 1999

    Google Scholar 

  12. Sathirakul K, Voelker JR, Teng LL, et al. Chronic renal insufficiency does not affect the pharmacokinetics of LY333531 or that of its active metabolite, compound LY338522. Clinical Pharmacology and Therapeutics 71: 10, Feb 2002

    Google Scholar 

  13. Eli Lilly and Company. Pilot Study of Ruboxistaurin Showed Favorable Effects on Kidney Damage and Function in People with Type 2 Diabetes and Nephropathy. Media Release: 12 Jun 2005. Available from URL: http://www.lilly.com

    Google Scholar 

  14. Eli Lilly and Company. Investigational Treatment Ruboxistaurin Demonstrated Promise in Reducing the Occurrence of Vision Loss Caused by Diabetic Retinopathy. Media Release: 11 Jun 2006. Available from URL: http://www.lilly.com

    Google Scholar 

  15. Crofskey, S. Ruboxistaurin a reality for reduced vision loss in diabetic retinopathy. Inpharma: No. 1552, 26 Aug 2006

  16. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728–731, 3 May 1996

    Article  PubMed  CAS  Google Scholar 

  17. Kowluru RA, Jirousek MR, Stramm L. Diabetes-induced disor- ders of retinal protein kinase C and Na,K-ATPase are inhibited by LY333531. Diabetes 45 (Suppl. 2): 16, May 1996

    Google Scholar 

  18. Danis RP, Bingaman DP, Jirousek M. Retinal neovascularization from experimental ischemia is inhibited by a PKC-beta inhibitor, LY333531. Diabetologia 40 (Suppl. 1): 17, Jun 1997

    Google Scholar 

  19. Early results of clinical trial data in diabetic eye study are promising Joslin researchers report. PR Newswire [online]: [2 pages], 23 Oct 1998. Available from URL: http://www.new-spage.com

    Google Scholar 

  20. Aiello LP, Bursell S, Devries T, et al. Protein kinase C beta- selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes 48 (Suppl. 1): 19, May 1999

    Google Scholar 

  21. Goueli SA. IBC’s 4th Annual Conference on Signal Transduc- tion Therapy: novel targets for therapeutic intervention. Expert Opinion on Investigational Drugs 7: 121–133, Jan 1998

    Article  PubMed  CAS  Google Scholar 

  22. Vinik A, Tesfaye S, Zhang D, et al. LY333531 treatment improves diabetic peripheral neuropathy with symptoms. Diabetes 51 (Suppl. 2): 79, Jun 2002

    Google Scholar 

  23. Litchy W, Dyck P, Tesfaye S, et al. Diabetic peripheral neuropathy assessed by neurological examination and composite scores is improved with LY333531 treatment. Diabetes 51 (Suppl. 2): 197–198, Jun 2002

    Google Scholar 

  24. Bastyr III E, Price K, Skljarevski V, et al. Ruboxistaurin mesy- late treatment in patients with diabetic peripheral neuropathy improves clinical global impression and correlates with change in patient symptoms and signs. Diabetes 52 (Suppl. 1): 191–192, Jun 2003

    Google Scholar 

  25. Skljarevski V, Bai S, Amador AG, et al. Ruboxistaurin mesylate improves positive sensory symptoms and neurological signs of diabetic peripheral neuropathy. Neurology 62 (Suppl. 5): 192–193 (plus poster) abstr. P03.003, No. 7, 28 Apr 2004

    Google Scholar 

  26. Skljarevski V, Mason T, Bastyr E. et al. Ruboxistaurin mesylate improves the signs and symptoms of diabetic peripheral neu ropathy. Journal of Pain 5 (Suppl. 1): 58, No. 3, Apr 2004

    Article  Google Scholar 

  27. Eli Lilly and Company. Data Show Reduced Symptoms of Diabetic Peripheral Neuropathy for Patients Taking Lilly’s Ruboxistaurin. Media Release: 6 Sep 2004. Available from URL: http://www.lilly.com

    Google Scholar 

  28. Eli Lilly and Company. Data Presented at ADA: Lilly’s Ruboxin, istaurin Mesylate May Reduce Moderate Visual Loss in People with Moderate to Severe Diabetic Retinopathy. Media Release: 14 Jun 2003. Available from URL: http://www.lilly.com

    Google Scholar 

  29. Milton R, Aiello L, Davis M, et al. Initial results of the protein kinase C b inhibitor diabetic retinopathy study (PKC-DRS). Diabetes 52 (Suppl. 1): 127, Jun 2003

    Google Scholar 

  30. Milton RC, Aiello LP, Davis MD, et al. Initial results of the protein kinase C beta inhibitor Diabetic Retinopathy Study. Diabetologia 46 (Suppl. 2): 42, Aug 2003

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruboxistaurin. Drugs R D 8, 193–199 (2007). https://doi.org/10.2165/00126839-200708030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708030-00007

Keywords

Search

Navigation